Moderna Settles $2.25 Billion Patent Dispute, Shares Jump 10% on Legal Clarity
The biotech resolves a long-running lipid nanoparticle infringement case with Arbutus and Genevant, clearing a path for its post-COVID vaccine portfolio.
Moderna shares surged more than 10% in extended trading Tuesday after the company agreed to pay up to $2.25 billion to settle patent litigation that had clouded its vaccine commercialization strategy.
The settlement with Arbutus Biopharma and Genevant Sciences, a subsidiary of Roivant Sciences, resolves all global disputes over lipid nanoparticle (LNP) delivery technology used in Moderna’s COVID-19 vaccines. Under the agreement, Moderna will pay $950 million upfront in July 2026, with an additional $1.3 billion contingent on the outcome of a federal appeal. The deal eliminates future royalty obligations across Moderna’s entire infectious disease portfolio, including its next-generation COVID shot mNEXSPIKE, RSV vaccine mRESVIA, and combination flu-COVID candidate mCOMBRIAX.
Removing a Legacy Overhang
The litigation centered on whether Moderna infringed patents held by Arbutus and Genevant covering LNP technology, the delivery mechanism that encapsulates mRNA and enables it to enter cells. According to STAT News, if the full $2.25 billion is paid, the settlement will rank among the largest in patent history. A trial in Delaware federal court had been scheduled to begin next week before the parties reached terms.
Moderna’s settlement includes consent to a judgment of infringement and no invalidity on four patents asserted by Arbutus and Genevant. In exchange, Genevant granted Moderna a global non-exclusive license to LNP delivery technology for SM-102-containing mRNA vaccines for infectious diseases, with a covenant not to sue on certain patents. The agreement closes all enforcement actions worldwide, including cases in the U.S. and internationally.
“Resolving this legacy matter from our pandemic response removes uncertainty and allows us to turn our full focus to Moderna’s exciting near-term future.”
— Stéphane Bancel, CEO, Moderna
The contingent $1.3 billion payment hinges on Moderna’s appeal to the Federal Circuit Court of Appeals. The company argues that Section 1498 of federal law grants it immunity from liability for patent infringement related to government contracts, shifting responsibility to U.S. taxpayers. If Moderna prevails on appeal, no additional payment is due. If the court affirms liability, the payment becomes due within 90 days. Moderna has stated it expects no accrual for the contingent amount, deeming the loss not probable.
Financial Implications and Path Forward
Moderna will record a $950 million charge in the first quarter of 2026. Despite the hit, the company projects ending the year with $4.5 billion to $5.0 billion in cash and cash equivalents, plus access to $900 million under its existing credit facility, for total liquidity of $5.4 billion to $5.9 billion. The settlement removes a significant uncertainty that had weighed on investor sentiment as Moderna attempts to transition from pandemic-era COVID revenues to a diversified vaccine franchise.
| Year | Total Revenue | Change |
|---|---|---|
| 2022 | $19.3B | — |
| 2023 | $6.8B | -65% |
| 2024 | $3.2B | -53% |
| 2025 (projected) | $1.5–$2.5B | -22% to +22% |
Moderna’s revenue has collapsed from pandemic peaks as global COVID vaccine demand normalized. According to BioPharma Dive, third-quarter 2025 revenue fell 45% year-over-year to $1 billion, driven primarily by reduced vaccination rates and increased competition. The company now expects up to 10% revenue growth in 2026, targeting cash breakeven in 2028 through aggressive cost reductions and expansion of its seasonal vaccine franchise.
The settlement provides clarity for Moderna’s pipeline commercialization. The company has regulatory submissions pending for mRNA-1010, a seasonal influenza vaccine with an FDA decision date of August 5, 2026, and mRNA-1083, a combination flu-COVID vaccine under review in Europe and Canada. Piper Sandler raised its price target on Moderna to $69 in February, citing growth prospects for mNEXSPIKE and a pipeline that includes late-stage oncology candidates developed with Merck.
Broader Patent War Continues
While Moderna has resolved the Arbutus/Genevant dispute, it remains engaged in multiple intellectual property battles. The company is pursuing affirmative patent claims against Pfizer and BioNTech over mRNA technology used in their COVID vaccine, while BioNTech has countersued. Arbutus and Genevant also have ongoing litigation against Pfizer and BioNTech over the same LNP technology, with that case still unresolved. According to Reuters, the Moderna case would have been the first COVID vaccine patent dispute to reach trial.
LNP technology is critical to mRNA vaccine efficacy. The lipid coating protects fragile mRNA molecules and facilitates cellular uptake. Multiple companies developed proprietary LNP formulations during the pandemic, leading to overlapping patent claims and a web of litigation over billions in vaccine sales.
What to Watch
Moderna’s Federal Circuit appeal on Section 1498 immunity will determine whether an additional $1.3 billion becomes payable, likely within the next 12 to 18 months. Investors will monitor FDA decisions on mRNA-1010 (flu) and mRNA-1083 (combo flu-COVID) as catalysts for 2026 revenue growth. The company expects approval of both vaccines this year, along with late-stage data from cancer and rare disease programs. Arbutus has indicated it is evaluating a return of capital to shareholders in Q3 2026 upon receiving the $950 million upfront payment. With the settlement, Moderna’s focus shifts from litigation defense to execution on product launches that must reverse three years of declining sales.